ATE326014T1 - Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma - Google Patents

Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma

Info

Publication number
ATE326014T1
ATE326014T1 AT99962732T AT99962732T ATE326014T1 AT E326014 T1 ATE326014 T1 AT E326014T1 AT 99962732 T AT99962732 T AT 99962732T AT 99962732 T AT99962732 T AT 99962732T AT E326014 T1 ATE326014 T1 AT E326014T1
Authority
AT
Austria
Prior art keywords
ldl
lipoprotein
vldl
compound
plasma cholesterol
Prior art date
Application number
AT99962732T
Other languages
English (en)
Inventor
Russell M Medford
Uday Saxena
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Application granted granted Critical
Publication of ATE326014T1 publication Critical patent/ATE326014T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99962732T 1998-11-09 1999-11-09 Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma ATE326014T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10764498P 1998-11-09 1998-11-09

Publications (1)

Publication Number Publication Date
ATE326014T1 true ATE326014T1 (de) 2006-06-15

Family

ID=22317677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962732T ATE326014T1 (de) 1998-11-09 1999-11-09 Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma

Country Status (10)

Country Link
EP (1) EP1137948B1 (de)
JP (1) JP2002529740A (de)
CN (1) CN1332849A (de)
AT (1) ATE326014T1 (de)
AU (1) AU1911200A (de)
CA (1) CA2350316A1 (de)
DE (1) DE69931279T2 (de)
IL (2) IL143057A0 (de)
MX (1) MXPA01004683A (de)
WO (1) WO2000028332A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
ES2283933T3 (es) 1997-05-14 2007-11-01 Atherogenics, Inc. Ester del acido succinico de probucol para la inhibicion de la expresion de vcam-1.
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
EP1967514B1 (de) 1999-10-04 2013-01-02 Nippon Soda Co., Ltd. Phenolverbindungen und Aufzeichnungselemente damit
JP2003528109A (ja) * 2000-03-21 2003-09-24 アセロジエニクス・インコーポレイテツド Ｖｃａｍ−１の発現を阻害するためのチオケタール及びチオエーテル
EP1272465A2 (de) 2000-04-11 2003-01-08 Atherogenics, Inc. Verfahren und zusammensetzungen zur erhöhung des hdl-plasmaspiegels
CA2440680C (en) 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
ITMI20020597A1 (it) * 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
WO2005102323A2 (en) 2004-04-20 2005-11-03 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
CN101686676A (zh) 2007-03-26 2010-03-31 沙路特里亚制药有限责任公司 用于治疗糖尿病的方法和普罗布考衍生物的组合物
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CA2765709A1 (en) * 2009-06-17 2010-12-23 Maine Standards Company, Llc Method for measuring lipoprotein-specific apolipoproteins
CN114085283A (zh) * 2015-05-19 2022-02-25 拉·约拉过敏反应及免疫医学研究所 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
CN109789217A (zh) * 2016-09-01 2019-05-21 凯文·乔恩·威廉姆斯 用于降低脂蛋白颗粒对动脉壁酶引起的致动脉粥样硬化性聚集的敏感度的方法和试剂盒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
DK1468692T3 (da) * 1993-12-10 2006-08-28 Aventis Inc Anvendelse af 2,6-di-alkyl-4-silyl-phenoler til behandling af xantom
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
CH691957A5 (de) * 1996-09-03 2001-12-14 Urs Tschudin Schleifmaschine.

Also Published As

Publication number Publication date
MXPA01004683A (es) 2002-09-18
JP2002529740A (ja) 2002-09-10
WO2000028332A9 (en) 2000-09-28
AU1911200A (en) 2000-05-29
WO2000028332A1 (en) 2000-05-18
DE69931279T2 (de) 2007-04-12
CA2350316A1 (en) 2000-05-18
EP1137948A1 (de) 2001-10-04
EP1137948B1 (de) 2006-05-10
CN1332849A (zh) 2002-01-23
IL143057A0 (en) 2002-04-21
IL143057A (en) 2010-04-15
DE69931279D1 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
ATE326014T1 (de) Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma
Roberts et al. A cell-based model of thrombin generation
Oka et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive
Barrans et al. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases
Marais et al. Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E
Bersot et al. Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts.
ZA200107598B (en) Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein Al, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol.
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
EP1155121A4 (de) Zusammensetzungen und verfahren zur regulierung des serumcholesterins
TW200510452A (en) Compositions and methods for treating atherosclerosis
AU2864195A (en) Class bi and ci scavenger receptors
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
IL160533A0 (en) Methods of screening molecules that are used to prevent cardiovascular diseases
Soutar et al. The characterization of lipoproteins in the high density fraction obtained from patients with familial lecithin: cholesterol acyltransferase deficiency and their interaction with cultured human fibroblasts.
DE69716057D1 (de) Verfahren und zusammensetzungen zum nachweis von spleiss-mutationen in dihydropyremudine dehydrogenase
de Man et al. Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase
De Cristofaro et al. Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro-and anticoagulant pathways in healthy subjects
Minnich et al. Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3'(Arg136–> His): association with mild dyslipidemia and double pre-beta very low density lipoproteins
Morton et al. Conversion of lipid transfer inhibitor protein (apolipoprotein F) to its active form depends on LDL composition
Caron et al. A blinded in vitro study with Refacto® mock plasma samples: similar FVIII results between the chromogenic assay and a one‐stage assay when using a higher cephalin dilution
Chung et al. Lipolytic remnants of human VLDL produced in vitro: effect of HDL levels in the lipolysis mixtures on the apoCs to apoE ratio and metabolic properties of VLDL core remnants
Adolph Cell cycle variations in ADP-ribosylation of HeLa nuclear proteins
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties